Nocion: Pulmatrix announces collaboration with Nocion Therapeutics
Two months after announcing the appointment of Nocion Therapeutics CEO Rick Batycky to its board, Pulmatrix has announced a deal with Nocion to look at the use of Pulmatrix's iSPERSE particle engineering technology for development of inhaled formulations of Nocion drugs. According to the Nocion web site, the company's lead candidate targets refractory chronic cough. [...]
Read full article »
Nocion is a Massachusetts-based biopharmaceutical company that researches and develops small-molecule therapies for the treatment of serious conditions including cough and itch.
Read more